Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Acquired Intangible Amortization

Similar metrics at other companies

UiPath logo
PATHReportable Segment — Acquired Intangible Amortization
$4.61M+227%
Leonardo DRS, Inc. logo
DRSASC — Acquired Intangible Amortization
$5M0.0%
Leonardo DRS, Inc. logo
DRSIMS — Acquired Intangible Amortization
$0
Charles Schwab Corporation logo
SCHWAdvisor Services — Acquired Intangible Amortization
$23M-4.2%
Charles Schwab Corporation logo
SCHWInvestor Services — Acquired Intangible Amortization
$119M+14.4%
Marvell Technology, Inc. logo
MRVLReportable Segment — Acquired Intangible Amortization
$225.2M-8.3%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Adjusted selling and marketing (1)58,16655,571
Adjusted general and administrative (1)25,71220,609
Stock-based compensation (1)13,53914,553
Amortization of acquired intangible assets14,32214,322
Changes in the fair value of contingent consideration(2,277)(2,675)
Legal settlement7,000
Other (2)8801,862
Total operating expenses170,474166,933

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — acquired intangible amortization?
Pacira BioSciences, Inc. (PCRX) reported business segments — acquired intangible amortization of $14.32M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — acquired intangible amortization changed year-over-year?
Pacira BioSciences, Inc.'s business segments — acquired intangible amortization decreased by 0.0% year-over-year, from $14.32M to $14.32M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — acquired intangible amortization?
Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — acquired intangible amortization has grown at a 0.0% compound annual growth rate (CAGR), from $57.29M to $57.29M.
What does business segments — acquired intangible amortization mean?
Represents the periodic non-cash charge allocated to the cost of intangible assets acquired through business combinations within the segment. This reflects the systematic expensing of the value assigned to acquired intellectual property or customer relationships over their useful lives.

Ask your AI about Pacira BioSciences, Inc.'s business segments — acquired intangible amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude